As of December 31, 2023, the Company had cash and cash equivalents of approximately $1.8 million. Subsequent to year end, in February 2024 the Company closed a public offering with participation from healthcare focused institutional investors for aggregate gross proceeds of $5.5 million. Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
- GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
- GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
- GRI Bio announces notice of allowance for Canadian patent
- GRI Bio receives MRHA authorization to conduct Phase 2a study of GRI-0621
